Prof. David Denning FRCP FRCPath DCH FMedSci

Professor of Infectious Diseases in Global Health

Research Focus

Aspergillosis, global health and fungal diseases, azole resistance in Aspergillus and genetics of allergic and chronic pulmonary aspergillosis

Scientific Activities

David Denning has published more than 500 papers, books and book chapters and lectures worldwide. His writings have been cited over 45,000 times. He has successfully lead many major international collaborative science, diagnostic and treatment projects and clinical guidelines, with subsequent publication in Nature, the New England Journal of Medicine, Sience and the Lancet.

He is the Founder of 2 University spinout biotechnology companies – F2G Ltd (antifungal drug discovery and development) and Myconostica Ltd (molecular diagnostic tests for fungi), now sold to Lab21. He is Chairman of the Editorial Board of The Aspergillus Website (1998-) with over 1 million pages read per month.He has chaired the Scientific Committees of several international fungal infection meetings, and co-chairs the alternate year Advances Against Aspergillosis meetings, attracting ~400 delegates for >120 countries.

He is President of the Global Action Fund for Fungal Infections which has a mission to greatly improve outcomes from fungal infections, through greater understanding of the burden of fungal diseases, advocacy for universal access to fungal diagnostic testing and antifungal therapies, and enhancing clinical skills through education.

Significant Publications

Denning DW, Bromley MJ. How to bolster a sparse antifungal pipeline. Science 2015;347:1414-6.

Denning DW, Cadranel J, Beigelman-Aubry C, Ader, F, Chakrabarti A, Blot S, Ullman A, Dimopoulos G, Lange C, European Society for Clinical Microbiology and Infectious Diseases and European Respiratory Society. Chronic pulmonary aspergillosis – Rationale and clinical guidelines for diagnosis and management. Eur Resp J 2016; 47:45-68.

Denning DW. How the UNAIDS target of reducing annual AIDS deaths below 500,000 by 2020 can be achieved. Phil Trans Roy Soc B 2017; 371: 20150468.

---

Collaborators